Stem-cell chairman takes on wider role
By Carl T. Hall,
San Francisco Chronicle
| 01. 07. 2005
Board names Klein president, gives him authority to hire staff
Robert N. Klein, the Palo Alto developer and stem-cell advocate, took on the crucial day-to-day management duties Thursday for California's $3 billion stem-cell program.
Klein, who already was serving as chairman of the 29-member oversight board directing the voter-approved California Institute for Regenerative Medicine, was named by that board to be interim president of the institute with authority to hire staff and find office space.
State voters created the institute in November by passing Proposition 71, which authorized up to $350 million a year in taxpayer-financed bonds to pay for research projects and facilities during the next decade. The main purpose of the grants will be to promote embryonic stem-cell research that can't be financed by the federal government under rules adopted by the Bush administration.
Stem cells are the early, undifferentiated cells that eventually turn into the many specific cell types of the body. Biologists say the cells are invaluable research tools that might be fashioned into cures for diseases that can't otherwise be treated effectively. Religious and other...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...